Therefore, new classes of drugs, such as farnesoid X receptor (FXR) agonists, glucagon-like peptide 1 (GLP-1) agonists, and thyroid hormone receptor-β (THR-β) agonists, are emerging for the treatment of NAFLD, nonalcoholic steatohepatitis (NASH), and fibrosis [9]. The gene discussed is GCG; the disease is metabolic dysfunction-associated steatohepatitis.